For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Walking the talk on equity and sustainability crucial in wake of report looking at health system
+Print Archive
Bulletin
Walking the talk on equity and sustainability crucial in wake of report looking at health system
Wednesday 1 July 2020, 12:15 AM

Sarah Dalton: Will fewer DHBs bring executive decision-makers closer to, or further away from, the clinical coalface?
ASMS
Sarah Dalton takes a look at the final report of the Health and Disability System Review Panel and urges readers to stay engaged in ongoing developments
As I drive into work on Tuesday 16 June, the radio is full of health news. Questions are being asked about the University of Otago’s decision to cut
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.